Valneva will work with local health authorities and wholesalers on the French island territory to distribute the vaccines.

Chikungunya cases have spiked substantially in La Réunion since early 2025, with 8,600 cases recorded and almost 3,000 new cases during the week of March 3 to 9, 2025 1. Similar to the 2005-2006 ...

Valneva’s 2024 Universal Registration Document – available in its entirety in French – includes the Company’s 2024 Annual Financial Report, the Company's Annual Management Report, the Board of ...

The agency has published a list of 24 high-risk infectious diseases as a reference tool for funders and researchers.

Valneva anticipates total product sales of €170 million to €180 million and total revenues of €180 million to €190 million for 2025, driven by increased IXCHIQ sales and growth in IXIARO and DUKORAL.

Within the framework of its CEPI agreement, Valneva also announced an exclusive license agreement with the Serum Institute of India (SII)17 to enable supply of its chikungunya vaccine in Asia.

The launch of the chikungunya vaccine in multiple regions contributed to initial sales of €3.7 million. Valneva reported an operating profit of €20.7 million, compared to a loss in the ...

Within the framework of its CEPI agreement, Valneva also announced an exclusive license agreement with the Serum Institute of India (SII) 17 to enable supply of its chikungunya vaccine in Asia. In ...

A mosquito-borne disease called chikungunya has killed two elderly people on France's Reunion Island, local authorities said ...

CEO Thomas Lingelbach highlighted that Valneva achieved double-digit year ... R&D costs are attributed to mandatory Phase 4 trials for chikungunya and the initiation of pediatric studies.

Valneva has claimed the accolade of becoming the first drugmaker to win FDA approval for a vaccine for chikungunya virus, a potentially life-threatening mosquito-borne disease. The French biotech ...